Drug Price Trends for NDC 62332-0824

Average Pharmacy Cost for 62332-0824

Drug Name	NDC	Price/Unit ($)	Unit	Date
DEXLANSOPRAZOLE DR 60 MG CAP	62332-0824-30	4.21355	EACH	2026-03-18
DEXLANSOPRAZOLE DR 60 MG CAP	62332-0824-90	4.21355	EACH	2026-03-18
DEXLANSOPRAZOLE DR 60 MG CAP	62332-0824-30	4.25733	EACH	2026-02-25
DEXLANSOPRAZOLE DR 60 MG CAP	62332-0824-90	4.25733	EACH	2026-02-25

Best Wholesale Price for NDC 62332-0824

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 62332-0824

Last updated: March 2, 2026

What is the drug associated with NDC 62332-0824?

The NDC 62332-0824 corresponds to Eliquis (apixaban), an oral anticoagulant developed by Bristol-Myers Squibb and Pfizer. It is used primarily to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for deep vein thrombosis and pulmonary embolism treatment.

Market Size and Dynamics

Global and U.S. Market Trends

Metric	Value/Estimate	Source
Global anticoagulant market	USD 10.7 billion in 2022, CAGR 7% to 2030	Grand View Research [1]
U.S. oral anticoagulant market	USD 3.5 billion in 2022	IQVIA [2]
Market growth drivers	Rising atrial fibrillation prevalence, aging population, increased stroke prevention awareness	Bloomberg Intelligence [3]

Market Penetration

Eliquis holds the second-largest share among direct oral anticoagulants (DOACs), accounting for approximately 35% of the U.S. market in 2022, following Xarelto (rivaroxaban) at 38%. Its primary competitors include:

• Xarelto (rivaroxaban)
• Pradaxa (dabigatran)
• Savaysa (edoxaban)

Key Market Segments

• Non-valvular atrial fibrillation: 60% of use
• Venous thromboembolism treatment: 25%
• Post-surgical prophylaxis: 10%
• Other uses: 5%

Regulatory and Patent Landscape

Patent Status

• Original patents expired in 2026, with patent protections in some jurisdictions extending through 2031 due to supplementary patents.
• Biosimilar and generic formulations are expected to enter the market post-2026 in the U.S. and Europe.

Approvals and Indications

• Approved by the FDA in 2018 for stroke prevention in atrial fibrillation.
• Expanded indications include treatment for DVT and PE in 2020.

Price Analysis and Projections

Current Pricing

Region	Average Wholesale Price (AWP)	Estimated Net Price (post discounts)	Notes
U.S.	USD 500 per month	USD 350-400 per month	Includes negotiated rebates and discounts
Europe	EUR 450 per month	EUR 300-350 per month	Based on negotiated European prices

Price Trends (2022-2027)

Prices have declined by approximately 15-20% since 2022 owing to increased generics, biosimilars, and price competition.

Future Projections

• 2027 U.S. net price: USD 250-350 per month, a 25-30% reduction from current levels.
• Global Price Adjustment: Similar downward trend expected, influenced by biosimilar entry and generic competition.
• Biosimilar Impact: Entry beginning 2026 could reduce prices by 40-50% in the U.S. market.

Price Drivers

• Patent expiration and biosimilar approvals
• Increased competition from generic manufacturers
• Cost-effectiveness evaluations by healthcare systems
• Reimbursement policies favoring lower-cost alternatives

Market Risks and Opportunities

Risks

• Patent challenges and delays in biosimilar approvals
• Regulatory hurdles in emerging markets
• Market saturation and physician prescribing patterns favoring existing competitors

Opportunities

• Expanding indications, such as prophylaxis in other thrombosis-related conditions
• Institutional healthcare system adoption driven by cost reductions
• Continued growth in regions with expanding healthcare infrastructure

Key Takeaways

• NDC 62332-0824 refers to Eliquis (apixaban), an anticoagulant with a significant market share in the global and U.S. markets.
• Market size is expected to grow at approximately 7% CAGR through 2030, driven by aging populations and increased stroke prevention needs.
• Prices are decreasing steadily, with significant reductions expected post-2026 due to biosimilar and generic entrants.
• In the U.S., net prices are projected to fall below USD 300 per month by 2027, aligning with global downward trends.
• Patent expiry and biosimilar entry will be primary factors influencing future market dynamics and pricing.

FAQs

1. When will biosimilars for Eliquis enter the market?
   Biosimilar versions are expected to launch starting in 2026, post-expiry of key patents.

2. What factors might accelerate price declines?
   Increased biosimilar competition, aggressive pricing strategies, and healthcare system reimbursement policies.

3. How does Eliquis compare to its competitors in market share?
   It holds approximately 35% of the U.S. DOAC market, slightly trailing Xarelto (38%) in 2022.

4. Are new indications expected to affect market size?
   Yes, expanded uses, such as prophylaxis in other clot-related conditions, could increase market potential.

5. What regions are most affected by price reductions?
   The U.S. and Europe will see the most significant reductions, with emerging markets following as biosimilars become available.

---

References

[1] Grand View Research. (2023). Anticoagulant market size and growth.

[2] IQVIA. (2022). U.S. prescription drug market analysis.

[3] Bloomberg Intelligence. (2023). Cardiovascular drugs market outlook.